MRG002

· Shanghai Miracogen Inc.

Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for MRG002, covering 2021-12-02 to 2025-03-12. Get the full timeline:

Most recent: Clinical Trial Update: Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary [Phase 2]